Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuta Nakamaru

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Drug Metabolism and Pharmacokinetics|May 25, 2024
Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modelingMizuki Uno, Yuta Nakamaru, Fumiyoshi Yamashita
In Vivo (Athens, Greece)|June 27, 2025
Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With RitonavirYuta Nakamaru, Ken-Ichi Sako, Naohito Ide, et al.
Pharmaceutical Research|July 9, 2026
Variance-Consistent Covariate Modeling from Posterior Summaries in Population PharmacokineticsJunya Ooka, Mizuki Uno, Yuta Nakamaru, et al.
Therapeutic Drug Monitoring|July 12, 2021
Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological MalignanciesKen-Ichi Sako, Yuta Nakamaru, Kazuro Ikawa, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2025
Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration dataSakiko Kimura, Ken-Ichi Sako, Nao Kikkawa, et al.
Biomedical Reports|August 11, 2022
Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumabTakeshi Chiba, Haruki Ujiie, Yukiko Yaegashi, et al.
Biomedical Reports|December 9, 2024
Effect of infusion time on risk of <i>Bacillus cereus</i> bloodstream infections in patients administered with BFLUID amino acid infusions via peripheral venous cathetersAtsushi Takano, Yuta Nakamaru, Ken-Ichi Sako, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Drug Metabolism and Pharmacokinetics|May 25, 2024
Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modelingMizuki Uno, Yuta Nakamaru, Fumiyoshi Yamashita
In Vivo (Athens, Greece)|June 27, 2025
Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With RitonavirYuta Nakamaru, Ken-Ichi Sako, Naohito Ide, et al.
Pharmaceutical Research|July 9, 2026
Variance-Consistent Covariate Modeling from Posterior Summaries in Population PharmacokineticsJunya Ooka, Mizuki Uno, Yuta Nakamaru, et al.
Therapeutic Drug Monitoring|July 12, 2021
Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological MalignanciesKen-Ichi Sako, Yuta Nakamaru, Kazuro Ikawa, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2025
Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration dataSakiko Kimura, Ken-Ichi Sako, Nao Kikkawa, et al.
Biomedical Reports|August 11, 2022
Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumabTakeshi Chiba, Haruki Ujiie, Yukiko Yaegashi, et al.
Biomedical Reports|December 9, 2024
Effect of infusion time on risk of <i>Bacillus cereus</i> bloodstream infections in patients administered with BFLUID amino acid infusions via peripheral venous cathetersAtsushi Takano, Yuta Nakamaru, Ken-Ichi Sako, et al.
Pageof 1